Recent Advances in RGD Peptide conjugated nanoparticles system as a new strategy for Targeted Therapy in Colon Cancer

The most common late malignancy of the gastrointestinal tract is the involuntary stage of colorectal cancer, which is a chronic disorder caused by cumulative structural and functional genetic changes. The RGD peptide is the most minor sequence with a high affinity to integrin, preventing different cell types. RGD peptide-conjugated pharmaceuticals hold significant promise for targeted drug delivery and imaging. Their ability to selectively bind to integrin-expressing cells offers the potential for improved treatment outcomes, reduced adverse effects, and enhanced disease detection and monitoring. Integrin is a type of cell adhesion molecule required for the growth and spread of colon cancer, Targeting these molecules with RGD peptides makes it possible to deliver drugs to the tumory and coronary cells and prevent damage to the body. Salem prevented. Drug carriers with RGD function have more therapeutic efficiency by increasing the drug and keeping it inside the tumor microenvironment. RGD peptides and their combinations can help identify and track cancer progress by using imaging agents and improving therapeutic prescriptions. Inhibition of integrins has reported promising results in various cases of colon cancer malignancies. Cilengitide (an αvβ۳ and αvβ۵ integrin inhibitor) and abituzumab (an αv integrin-specific antibody), designed to inhibit the interaction between integrins and their ECM ligands in clinical trials. encouraging to work on other strategies. Considering the extent of recent indications, investigation of ECM-independent signaling of integrins, cancer cell survival and drug resistance are new approaches. In colon cancer nanotherapy, most importantly, clinically effective carriers with circulation time close to RBC (red blood) are needed. As a result, Integrins are molecules that can be used to deliver drugs to cancer cells prevent tumors in colon cancer, and are effective drug carriers in nanotherapy. This review article was performed within articles published at PubMed, Science Direct, and Google Scholar until May ۲۰۲۴. The keywords were RGD peptide and RGD peptide-conjugated nanoparticle and colorectal cancer.Searching these databases An initial search yielded ۱۹ articles. After reviewing the titles, nine articles were excluded. From the remaining ten articles, abstracts were read, and ۱۰ were selected based on inclusion criteria.

کلیدواژه ها:

RGD peptide ، Colon Cancer ، RGD Peptide conjugated nanoparticles ، Target Therapy